on Immunic AG
Immunic Secures USD 400 Million to Advance Commercial Ambitions
Immunic AG announced the successful completion of an oversubscribed private placement, raising up to USD 400 million. The initial USD 200 million is earmarked to conclude the Phase 3 ENSURE trials for relapsing multiple sclerosis and start trials for primary progressive multiple sclerosis, aiding its transition into a commercial-stage entity.
Key leadership changes accompany this strategic shift. Simona Skerjanec, a former Roche executive, is appointed interim Chairperson of the Board. Thor Nagel of BVF Partners joins the Board to guide the company’s commercial transformation. Additionally, a new CEO with a commercial background will be recruited.
The financing, supported by BVF Partners and other investors, underscores Immunic's commitment to developing vidofludimus calcium, a potential game-changer in multiple sclerosis treatment.
With strategic leadership and financial reinforcement, Immunic aims to enhance neurologic health innovations.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Immunic AG news